A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT06948422
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Orforglipron — DRUGAdministered orally.
- Placebo — DRUGAdministered orally.
Study Details
The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.
Key Dates
- Start date
- Apr 30, 2025
- Status verified
- May 2026
- Primary completion
- Sep 30, 2027
- Completion
- Sep 30, 2027
Study Design
- Enrollment
- 974 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SCREENING
Arms
- Experimental: Orforglipron (GZL1)Participants will receive orforglipron orally or placebo.
- Experimental: Orforglipron (GZL2)Participants will receive orforglipron orally or placebo.
Primary Outcome Measure
Number of Participants Allocated to Each ISA [ Time Frame: Week -8 to Week 0 ]
Locations (29)
Find similar trials in Phoenix, AZ
By condition
By specialty
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Effect of Electro-Acupuncture on Blood PressureRecruiting · University of California, Irvine · Irvine, California
- : Vascular Function in Health and DiseasePHASE1 · Recruiting · Russell Richardson · Salt Lake City, Utah
- Clinical and Molecular Characteristics of Primary Aldosteronism in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland